.jpg "Theravance Biopharma (NASDAQ: TBPH)")
In a report released yesterday, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Theravance Biopharma (TBPH), with a price target of $55. The company’s shares closed yesterday at $24.79.
Chen commented:
“. Post a solid quarter of execution, we are reiterating our OW rating and 12-month PT of $55 for TBPH shares. We believe the Street is underestimating the peak sales potential of TBPH’s key pipeline drugs. We think the commercialization of these programs could drive upward earnings revisions to levels not reflected in consensus expectations. Over time, TBPH expects to forward integrate from a royalty model to profit sharing and, ultimately, to building its own commercial infrastructure.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 13.1% and a 42.7% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.
Currently, the analyst consensus on Theravance Biopharma is a Moderate Buy with an average price target of $55.
See today’s analyst top recommended stocks >>
The company has a one-year high of $35.48 and a one-year low of $21.27. Currently, Theravance Biopharma has an average volume of 182.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Theravance Biopharma, Inc. operates as a biopharmaceutical company, which focuses on the discovery, development and commercialization of small molecule medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
